{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:17:12Z","timestamp":1790979432140,"version":"4.1.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Generalized pustular psoriasis (GPP) is a rare, chronic, often unpredictable, severe multisystemic autoinflammatory skin disease from which patients can experience flares, episodes of widespread eruptions of painful, sterile pustules often accompanied by systemic symptoms. The impact of GPP flares and underlying GPP severity on the healthcare resource utilization (HCRU) is not well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To quantify HCRU among US GPP patients by flare status and underlying severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Outpatient electronic health record (EHR) data (2017-2023) from the OMNY Health platform were linked with claims. Patients were indexed at first EHR GPP diagnosis code and followed for 1 year. GPP flares were identified from a previously developed algorithm. All-cause hospitalizations, emergency department\/urgent care (ED\/UC), and outpatient visits were summarized by flare status and underlying severity. Pharmacy and total gross charges were described by number of flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 335 patients were included. Patients who flared in the follow-up period (n = 205) had more hospitalizations than patients who did not flare (n = 130; 12.2% vs 6.9%; mean: 0.26 vs 0.09). ED\/UC visits were similar between groups (22.9% vs 27.7%; mean: 0.54 vs 0.45), while outpatient visits were greater among patients who did not flare (69.8% vs 78.5%; mean: 5.37 vs 6.56). For patients with 0, 1, and \u22652 flares with HCRU, mean pharmacy charges ($19,887, $25,180, and $57,674, respectively) and total gross charges ($29,196, $40,079, and $52,940, respectively) increased monotonically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GPP patients who flared and had more severe disease had greater HCRU and charges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/24755303251317193","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T18:16:06Z","timestamp":1738001766000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Healthcare Resource Utilization Among Patients With Generalized Pustular Psoriasis: The Impact of Flares and Disease Severity"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-4711","authenticated-orcid":false,"given":"Megan H.","family":"Noe","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Lavasani","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0445-6123","authenticated-orcid":false,"given":"Lawrence","family":"Rasouliyan","sequence":"additional","affiliation":[{"name":"OMNY Health, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Laouri","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L. W.","family":"Rhoads","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"e_1_3_4_2_2","volume-title":"Pustular Psoriasis: Pathogenesis, Clinical Manifestations, and Diagnosis","author":"Kalb RE","year":"2022","unstructured":"Kalb RE. Pustular Psoriasis: Pathogenesis, Clinical Manifestations, and Diagnosis. UpToDate; 2022. https:\/\/www.uptodate.com\/contents\/pustular-psoriasis-pathogenesis-clinical-manifestations-and-diagnosis"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/24755303211021786"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000529274"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00881-0"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00664-x"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1708193"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00493-0"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18851"},{"key":"e_1_3_4_10_2","article-title":"FDA approves Spevigo for treatment of generalized pustular psoriasis flares in adults","author":"Gallagher A","unstructured":"Gallagher A. FDA approves Spevigo for treatment of generalized pustular psoriasis flares in adults. Pharmacy Times. https:\/\/www.pharmacytimes.com\/view\/fda-approves-spevigo-for-treatment-of-generalized-pustular-psoriasis-flares-in-adults","journal-title":"Pharmacy Times"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563"},{"key":"e_1_3_4_12_2","unstructured":"Rasouliyan L Kumar V Walton SE et al. Identifying generalized pustular psoriasis flares using natural language processing of unstructured clinical notes and structured procedure. In Presented at 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2023) Halifax Nova Scotia Canada; August 23\u201327 2023."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S444238"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.6497"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2023.03.012"},{"key":"e_1_3_4_16_2","first-page":"89","article-title":"Economic burden of generalized pustular psoriasis in Sweden: a population-based register study","volume":"12","author":"L\u00f6fvendahl S","year":"2022","unstructured":"L\u00f6fvendahl S, Norlin JM, Schmitt-Egenolf M. Economic burden of generalized pustular psoriasis in Sweden: a population-based register study. Psoriasis (Auckl). 2022;12:89-98.","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16084"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1894108"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/24755303211021786"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/24755303211021779"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4640"}],"container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303251317193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24755303251317193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303251317193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:37:50Z","timestamp":1777509470000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24755303251317193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/24755303251317193"],"URL":"https:\/\/doi.org\/10.1177\/24755303251317193","relation":{},"ISSN":["2475-5303","2475-5311"],"issn-type":[{"value":"2475-5303","type":"print"},{"value":"2475-5311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}